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Patient-derived in vitro cultures of colorectal cancer (CRC) may help guide
treatment strategies prior to patient treatment. However, most previous studies
have been performed on a single biopsy per tumor. The purpose of this study
was to analyze multiple spatially distinct biopsies from CRCs and see how well
intratumor heterogeneity (ITH) was recapitulated in matching patient-derived
spheroids. Three to five biopsies were collected from six CRC tumors. Each
biopsy was split in two; one half was used for spheroid culturing, while the other
half was used for DNA and RNA purification. For two patients, lymph node
metastases were analyzed. Somatic mutations were called from whole exome
sequencing data. Each tumor contained mutations shared across all biopsies and
spheroids, including major CRC drivers such as APC, KRAS, and TP53. At the
same time, all tumors exhibited ITH on both mutation and copy number level.
The concordance between biopsies and spheroids ranged between 40 and 70%
for coding mutations. For three patients, the biopsy and spheroid from match-
ing areas clustered together, meaning that the spheroid resembled the area of
origin more than the other areas. However, all biopsies and spheroids contained
private mutations. Therefore, multiple cultures from spatially distinct sites of the
tumor increase the insight into the genetic profile of the entire tumor. Molecular
subtypes were called from RNA sequencing data. When based on transcripts
from both cancer and noncancerous cells, the subtypes were largely independent
of sampling site. In contrast, subtyping based on cancer cell transcripts alone
was dependent on sample site and genetic ITH. In conclusion, all examined
CRC tumors showed genetic ITH. Spheroid cultures partly reflected this ITH,
and having multiple cultures from distinct tumor sites improved the representa-
tion of the genetic tumor subclones. This should be taken into account when
establishing patient-derived models for drug screening.
Abbreviations
AF, allele frequency; Cf-em, cell fraction estimate; CIN, chromosomal instable; CMS, consensus molecular subtypes; CNA, copy number
alteration; CRC, colorectal cancer; FFPE, formalin-fixed and paraffin-embedded; H&E, hematoxylin and eosin; IGV, Integrative Genomics
Viewer; ITH, intratumor heterogeneity; LCM, laser capture microdissection; LNM, lymph node metastasis; LOH, loss of heterozygosity;
PDO, patient-derived organoid; PDX, patient-derived xenograft; PE, purity estimate; Pt., patient; SNV, single nucleotide variation; SSC,
sessile serrated CRC; WES, whole exome sequencing.
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1. Introduction
Colorectal cancer (CRC) is among the leading causes of
cancer-related deaths in the Western World. In recent
years, several studies have documented that CRC is
characterized by a considerable intertumor heterogene-
ity, indicating that it is not a single entity disease (Bram-
sen et al., 2017; De Sousa E Melo et al., 2013; Marisa
et al., 2013; Sadanandam et al., 2013). Consistent with
this, the existence of four consensus molecular subtypes
(CMS) of CRC was recently proposed (Guinney et al.,
2015) and shown to resolve much of the intertumor
molecular heterogeneity. Building on this approach, we
recently demonstrated how knowledge of molecular
subtypes improves the ability to identify and validate
prognostic biomarkers (Bramsen et al., 2017), and we
foresee that molecular subtyping in the future will lead
to improved treatment strategies for CRC. A further
complicating factor for molecular subtyping is the intra-
tumor heterogeneity (ITH) that arises during tumor
development. After the initial tumorigenic events lead-
ing to the malignancy, subclonal mutations are believed
to accumulate due to continued genetic instability.
These events can be either driver or passenger mutations
in relation to tumor evolution. The consequence is co-
existence of genetically distinct subclones within the
tumor, potentially with phenotypic differences, for
example, in growth, immunogenicity, vascularization,
invasiveness, drug response, and metastatic potential
(Burrell et al., 2013). Personalized treatment strategies,
based on drug screens performed on patient-derived
models prior to patient treatment, may be a solution to
overcome these issues. Primary models of CRC such as
cancer tissue-originated spheroids and patient-derived
organoids (PDOs) are being established with increasing
success rate (Ashley et al., 2014; Jeppesen et al., 2017;
Kondo et al., 2011; Sato et al., 2011; Sch€utte et al.,
2017; van de Wetering et al., 2015). These 3D culturing
systems increase the success rate of primary cultures and
resemble the primary tumor better than traditional one-
dimensional cell culturing (Weiswald et al., 2015). Most
studies find an overall genetic resemblance between the
primary tumor and the established model even after
long-term culturing. Yet, for some patients, they find up
to 80% discordant mutations between the primary
tumor and the model system (Sch€utte et al., 2017). Most
previous studies have been performed with a single
biopsy per tumor. Therefore, it is unknown how well
the ITH is reflected in the models. There is a need for
analyzing multiple cultures per patient to establish how
well these models actually represent the genetic ITH of
the primary tumor. The aim of this study was to
characterize the ITH within CRC and investigate how
well it is reflected in matching spheroids derived from
multiple spatially distinct sites of the primary tumor.
2. Materials and methods
2.1. Collection of colorectal cancer tissue
samples
Tumor samples from previously untreated patients were
collected at The Surgical Research Unit at Herning
Regional Hospital, Denmark. All patients gave written
informed consent, and the study was approved by The
Central Denmark Region Committees on Health
Research Ethics (J. no 1-10-72-221-14). To assess ITH,
three to five tumor regions were biopsied, depending on
the largest tumor diameter of 3 cm or 5 cm, respectively
(as illustrated in Fig. 1A). The biopsies were collected
immediately after surgery (within 30 min). Ischemia
times were not registered. Biopsies were taken from the
luminal surface from spatially distinct regions of the
tumor (east, west, north, south, and from the center).
Though a central biopsy was collected only if tumor
diameter was > 5 cm. The biopsies were resected by
scalpel and were approximately 1 cm*0.5 cm*0.5 cm in
size. Each biopsy was divided into two. One half was
snap-frozen in liquid nitrogen and stored at 80 °C for
later histochemistry, DNA and RNA purification. The
other half was placed in 5 °C transport medium [ad-
vanced DMEM/F12 supplemented with 100 UmL1
Gibco penicillin, 100 lgmL1 Gibco streptomycin (Life
Technologies, Carlsbad, CA, USA), and 2.5 lgmL1
amphotericin (Sigma-Aldrich, St. Louis, MO, USA)].
Fresh samples were transported overnight at 5 °C to
2cureX, for the formation of primary spheroid cultures
and subsequently DNA and RNA extraction. Six
patients were selected for this analysis; however, only
four of the patients’ tumors were analyzed by both
whole exome sequencing (WES) and RNA sequencing.
The remaining two tumors were either analyzed by
WES or RNA sequencing, respectively. Clinical details
are available in Table S1, and a complete sample over-
view is available in Table S2. Two of the five patients
had lymph node metastases (LNMs) at surgery. These
were formalin-fixed and paraffin-embedded (FFPE) and
obtained for DNA extraction.
2.2. Laser capture microdissection
From each fresh-frozen biopsy, a 4-lm section was cut
for hematoxylin and eosin (H&E) staining for a histo-
logical overview. Only samples with cancer cell content
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above 60% were included in the study, to avoid a
dominating signal from stromal cells. Biopsies origi-
nally presenting with < 60% cancer cells were
subjected to laser capture microdissection (LCM) to
enrich the cancer cell fraction. For LCM, nine sections
of 7 lm were cut, mounted onto Arcturus PEN
Fig. 1. Whole exome sequencing (WES) of multiple primary tumor areas, matched spheroids, and lymph node metastases. (A) Experimental
workflow. The biopsies were collected from spatially distinct regions of the tumor (at least 1 cm apart). (B) Mean target coverage of 79X
(range 41–225X) from WES. (C) Equal distribution of silent, missense, and nonsense SNVs was observed across samples. (D) Two different
mutational patterns were seen when comparing shared SNVs (common for n samples or n1) and regional SNVs (< n1 samples). The
pattern observed in the shared SNVs is dominated by C>T mutations in CpG sites, which is a typical age-related mutational mechanism. (E)
Sample information (T = tumor; S = spheroid; L = lymph node metastasis); tumor purity estimates (PE) (%) by Histology, PurBayes (WES
data), Sequenza (WES data), and ESTIMATE (RNA sequencing data). *LCM; -: not applicable. For most patients, the tumor PEs were higher
in the cultures compared to the primary biopsies. (F) CRC drivers (blue) and other tumor drivers (green) were identified through the IntOGen
catalog of cancer drivers (blue scale = allele frequency (AF); gray = no calls; white = no calls and < 10 reads). Possible drug targets are
marked with an *. In general, mutations in main cancer drivers for CRC (such as TP53, APC, KRAS, DCC, and BRAF) were observed across
all samples from each patient. Only one exception from this was observed (TP53 mutation not observed in patient 1_LNM), which was
most likely due to too low coverage (< 10 reads). Later-occurring driver mutations were only present in a subset of the samples from each
patient, and furthermore present in lower AFs.
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membrane glass slides (Life Technologies), and stained
with Histogene LCM Frozen Section Staining Kit
(Life Technologies) using the manufacturer’s protocol,
and subsequently stored at 80 °C until LCM. LCM
was performed on an Arcturus Veritas 704 (Arcturus
Bioscience Inc., Mountain View, CA, USA) and cap-
tured on CapSure Macro LCM caps (Thermo Fisher
Scientific, Waltham, MA, USA).
2.3. Spheroid preparation
Spheroids were established using a modified version
(Jeppesen et al., 2017) of a previously published proto-
col (Kondo et al., 2011). In brief, the tumor tissue was
washed in PBS with antibiotics (500 UmL1
penicillin, 500 lgmL1 streptomycin, 100 lgmL1
gentamicin, and 2.5 lgmL1 amphotericin B) (Sigma-
Aldrich). Fatty and necrotic areas were cut away with
a scalpel, and the tissue was minced into 1- to 2-mm
pieces. The minced tissue was washed repeatedly in
PBS with antibiotics until the PBS stayed clear. Tissue
was digested with 1 mgmL1 collagenase type II (Life
Technologies) in PBS with antibiotics for 30–45 min at
37 °C. The tissue suspension was filtered through a 70-
lm cell strainer (BD Biosciences, San Jose, CA, USA).
Retained tissue was redigested for 15–30 min at 37 °C
and passed through the filter again. This step was
repeated until all tissues passed through the cell strai-
ner. The flow-through was resuspended in StemPro
hESC SFM (Life Technologies) supplemented with
antibiotics (200 UmL1 penicillin, 200 lgmL1 strep-
tomycin, 100 lgmL1 gentamicin, and 2.5 lgmL1
amphotericin B) and seeded in petri dishes coated with
a thin layer of 1% agarose (Sigma-Aldrich) in PBS to
avoid cell adherence. Cells were cultured at 37 °C in a
5% CO2 humidified incubator for 1–8 days until
spheroids had formed. The success rate of establishing
cultures was 83%.
For DNA purification, spheroids were washed in
PBS to detach debris and loosely attached cells and
afterward filtered through a 40-lm cell strainer. Spher-
oids retained in the cell strainer were lysed in Cell
Lysis Solution with 5 mgmL1 Puregene Proteinase K
(Qiagen, Hilden, Germany) and stored at 80 °C.
2.4. DNA and RNA purification
DNA was isolated from fresh-frozen tissue samples
and lysed spheroids using the Gentra Puregene Tissue
kit (Qiagen). GenElute-linear polyacrylamide (Sigma-
Aldrich) was added as a carrier to enhance the out-
come. DNA concentrations were quantified using the
Qubit dsDNA Broad Range assay (Life Technologies).
DNA from FFPE tissue was purified using QIAamp
DNA FFPE Tissue Kit (Qiagen). RNA purification
was performed using RNeasy mini kit (Qiagen), and
RNA quality was measured using Agilent RNA 6000
Nano/Pico Kits on an Agilent 2100 Bioanalyzer (Agi-
lent Technologies, CA, USA). DNA and RNA were
stored at 80 °C until analysis.
2.5. Whole exome sequencing and data
processing
WES was performed using the KAPA-Hyper prep kit
from Illumina (Roche, Basel, Switzerland) for library
construction, followed by exome capture using Nim-
bleGen SeqCap EZ Human Exome Library v3.0
(Roche). Sequencing was performed on an Illumina
NextSeq500, with 10–50 ng of genomic DNA as input
per sample (depending on material available). Reads
were mapped using BWA MEM against the human
reference genome HG19, and duplicates were marked
with Picard MarkDuplicates. SNPs were called using
GATK HaplotypeCaller. Somatic mutations were
called using MuTect2, with matched germline WES
data obtained from blood samples as reference. Muta-
tion allele frequencies (AFs) were calculated using
SAMtools mpileup. Copy number alterations (CNAs)
and allelic imbalance were estimated using FACETS
(Shen and Seshan, 2016). Tumor purity was estimated
using PurBayes (Larson and Fridley, 2013) and
Sequenza (Favero et al., 2015). Tumor drivers and
potentially druggable targets were identified using the
IntOGen catalog of cancer drivers, available for down-
load at Intogen.org (Tamborero D, Rubio-Perez C,
Deu-Pons J, Schroeder M, Vivancos A, Rovira A,
Tusquets I, Albanell J, Rodon J, Tabernero J, Dienst-
mann R, Gonzalez-Perez A and Lopez-Bigas N,
unpublished data).
2.6. Phylogenetic analysis and heatmaps
Phylogenetic trees were generated as previously
described (Thomsen et al., 2016). Shortly, we used the
presence/absence of each single mutation to score each
possible rooted phylogenetic tree and the highest scor-
ing tree was used. The length of the branches is pro-
portional to the number of mutations supporting this
separation. The origin of the tree is the ancestral clone
where the first mutation occurred.
Heatmaps were created using the function aheatmap
from the R package, NFM, with ‘binary’ distance and
the linkage method ‘average’. All somatic single
nucleotide variations (SNVs; missense, nonsense, and
silent) supported by two or more reads in a given
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sample, and absent in the matched germline (0–1
read), were included. To avoid false negatives, regional
mutations with less than ten reads in negative samples
were not included in the heatmaps.
2.7. RNA sequencing and data processing
RNA sequencing was performed as previously described
using ScriptSeq RNA-Seq Library preparation Kit from
Illumina (Hedegaard et al., 2016). The paired raw
sequence reads were processed using TopHat2 (Kim
et al., 2013) and mapped to the human reference gen-
ome HG19. FPKM values were called using Cufflinks
(Trapnell et al., 2010) and GenCode v19 transcript
information. The FPKM gene expression values were
used to assign a molecular subtype to each sample using
our previously reported TUMOR subtype classifier
(Bramsen et al., 2017). CMS were assigned using the
nearest-centroid Single Sample Predictor CMS classifier
(Guinney et al., 2015), and CRIS types were assigned
using the CRIS classifier (Isella et al., 2017). Tumor
purity was estimated from the RNA sequencing data
using ESTIMATE (Yoshihara et al., 2013).
2.8. Data availability
WES and RNA sequencing data are available via
European Genome-phenome Archive (EGA) under
EGA study ID EGAS00001002684. The sample IDs
submitted to the EGA are available in Table S2.
3. Results
3.1. Genomic characterization of multiple primary
tumor areas and matched spheroids
We performed multiregional WES on tumor material
from five CRC patients. Each tumor was biopsied at
three to five spatially distinct sites, and each biopsy was
divided into two. One half was dissociated and grown as
spheroid culture, while the other half was snap-frozen
(Fig. 1A). For two patients, regional LNMs were identi-
fied during pathological examination of the resected
tumor specimen. The cancer percentage of each biopsy
was assessed by histology, and all samples with a cancer
percentage below 60% were purified by LCM before
DNA and RNA extraction. DNA from tumor biopsies,
spheroids, and LNMs were analyzed by WES. The
mean target coverage obtained was 79X (range 41–
225X) (Fig. 1B). A similar distribution of silent, mis-
sense, and nonsense SNVs was observed across samples
(Fig. 1C). For all patients, two different mutational pat-
terns were observed when comparing shared mutations
(common for n or n1 samples) to regional mutations
(common for < n1 samples) (Fig. 1D). C>T mutations
were dominant in the shared mutations and occurred
predominantly in a CpG site context (P < 2.2e-16, Pear-
son’s chi-squared test), consistent with an age-related
mutational mechanism (Milholland et al., 2015). Regio-
nal mutations were characterized with a lower frequency
of C>T mutations and in some patients, an increase in
C>A mutations. We estimated the cancer cell purity of
each sample using a variety of methods: histology, WES
data (PurBayes and Sequenza), and RNA sequencing
data (ESTIMATE). The purity estimates ranged
between 13 and 100% among the samples. The concor-
dance between the different methods was low, although
they followed the same tendencies (Fig. 1E). Generally,
the spheroids were estimated to be purer than the
matching tumor biopsies (P = 0.02, paired Wilcoxon
signed rank test) (Fig. 1E). Analysis of known cancer
driver genes, as defined by IntOGen (Tamborero D,
Rubio-Perez C, Deu-Pons J, Schroeder M, Vivancos A,
Rovira A, Tusquets I, Albanell J, Rodon J, Tabernero
J, Dienstmann R, Gonzalez-Perez A and Lopez-Bigas
N, unpublished data), revealed a striking mutational
pattern. For each patient, the shared driver genes were
significantly enriched for genes known to drive CRC
pathogenesis, such as APC, KRAS, BRAF, DCC, and
TP53. By contrast, the regional driver genes were
enriched for genes without a strong link to CRC
(P = 0.0006, Pearson’s chi-squared test). Furthermore,
the variant AFs of regional drivers were typically lower,
indicating that the mutations were subclonal within the
sample (Fig. 1F). Cancer drivers are obvious drug tar-
gets. Therefore, we investigated whether potentially
druggable drivers were present in all samples or only in
a subset. Possible drug targets were identified using the
IntOGen database; some were shared, while others were
regional (Fig. 1F). Mutations in potentially druggable
genes were shared across all samples for each patient in
11 of 27 events, and all patients had at least one shared
mutation in a potentially druggable gene. For example,
BRAF was mutated in all tumor, spheroid, and LNM
samples of patient 2 (pt. 2), and therefore, a target that
would likely allow the majority of pt. 20s cancer cells to
be targeted.
3.2. Genetic intratumor heterogeneity in the
primary tumor and lymph node metastases
Two patients in this study were stage III presenting
with local LNMs. To compare the genetic heterogene-
ity within tumors and their LNMs, phylogenetic trees
and heatmaps were created based on all mutations
identified in each sample (silent, missense, and
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nonsense). For both patients, the trees indicated that
seeding of the LNMs had happened from a clone ances-
tral to those currently found in the tumor. After seeding
of the metastases, the clones evolved in separate direc-
tions in the LNMs and in the tumor (Fig. 2). For pt. 1,
one LNM was analyzed and its mutational pattern was
equally consistent with the patterns observed in either of
the tumor areas. Accordingly, it cannot be determined
from which tumor area the cell seeding the metastasis
originated (Fig. 2A,B). For pt. 2, seven distinct LNMs
were analyzed. The phylogenetic tree indicated a very
close relationship between them (Fig. 2A), suggesting
that they probably all originated from the same original
clone. Furthermore, this clone most likely originated
from tumor area 2 (T2), as T2 is closest to the LNMs in
the phylogenetic tree (Fig. 2A). Consistent with this, the
mutational pattern of the LNMs is observed in T2, but
not in the two other tumor areas (T1 and T4) (Fig. 2B).
We also noticed a set of mutations common for all
tumor areas, but not seen in the LNMs (Fig. 2B), indi-
cating that they originate from a nonmetastatic sub-
clone. If we had not analyzed the LNMs, these
mutations would most likely have been interpreted as
ancestral. Taken together, our data indicate that at the
time of metastatic seeding at least two distinct clones
co-existed in the tumor. It is worth noticing that at the
time of diagnosis, the metastatic clone only constituted
a minor fraction of the primary tumor, being found in
only one of three tumor regions examined, as modeled
in Fig. 2C. Meaning that by analysis of a single biopsy
from the tumor, critical information about the meta-
static clone could easily have been missed. Interestingly,
the nonmetastatic clone had a mutation in TGFBR-II,
which is known to reduce the metastatic potential
(Fig. 2B) (Armaghany et al., 2012). The metastatic
clone, on the other hand, had several mutations associ-
ated with increased metastatic potential. These included
an inactivating (nonsense) mutation in the metastasis
inhibiting IL31 receptor gene (IL31RA) (Davidi et al.,
2017), and a missense mutation in lysophosphatidic acid
receptor 4 (LPAR4). LPAR receptors 1-6 have been
implicated in various prometastatic functions in differ-
ent cancer types (Willier et al., 2013). However, LPAR4
seems to have an antagonistic motility impact on CRC
cells (Lee et al., 2008), and a recent study showed that
knockdown of LPAR4 increased motility of CRC cells
(Takahashi et al., 2017).
3.3. Genetic intratumor heterogeneity in the
primary tumor and spheroids
Spheroid cultures have been suggested as in vitromodels
of primary cancers. To address how well spheroid
cultures reflect the genetic ITH observed in primary
CRC tumors, matched spheroids and biopsies from
multiple tumor regions were analyzed. The phylogenetic
trees (Fig. 3A) and mutational heatmaps (Fig. 3B) were
generated based on nonsense, missense, and silent SNVs
called from WES profiles. A long ancestral trunk with
shared mutations across all samples was common for all
patients (Fig. 3A). When comparing the distance (num-
ber of mutations distinguishing samples in the phyloge-
netic tree) between matching tumor biopsy and spheroid
pairs, there was a greater similarity between the muta-
tional profile of matched tumor biopsies and spheroid
pairs than between biopsies from different areas in the
tumor (P = 0.03, Wilcoxon rank sum test). However,
this could simply be due to less heterogeneity in the
spheroids and thereby shorter private branches. For
some patients (pt. 1, 4, and 5), the matched tumor biop-
sies and spheroids clustered together. However, for
others (pt. 2 and 3), there was no clear connection
between the matched tumor biopsies and spheroids. For
pt. 3, the tumor samples cluster together, indicating dis-
similarity between the matched spheroids and tumor
regions (Fig. 3A). Patient 3 also stands out by having
lower AFs in the spheroid cultures, particularly spher-
oid 2, than in the matching biopsies (Fig. 3B). This
could indicate that the spheroid cultures contained non-
mutated cells, potentially adenoma cells, which might
also explain the unusual clustering. For most patients,
the AFs in spheroids were higher than the primary biop-
sies (Fig. 3B), indicating that spheroids generally had a
higher cancer cell content than the biopsies.
Notably, all samples had private mutations, which
constituted on average 10% of the observed mutations
(range 3–18%). Pairwise private mutations observed
only in the biopsy and spheroid from the same loca-
tion were observed across all patients but to varying
degrees [on average, they constitute 6% of all muta-
tions (range 2–10%)]. For pt. 2, the mutations present
in the metastatic and nonmetastatic clones (illustrated
in Fig. 2B) were also present in the spheroids
(Fig. 3B). The mutations from the nonmetastatic clone
were present in all spheroid cultures. The metastatic
clone, on the other hand, was only evident in spheroid
culture 2, consistent with this clone being identified
only in biopsy 2 (Figs 2 and 3B). However, only some
of the mutations were called and these were present in
very low AFs. This indicates that the metastatic clone
was a minor clone in the spheroid 2 culture; hence,
uncalled mutations from the metastatic clone might be
false negatives.
Both the private and pairwise private mutations
from the biopsies and the spheroids were a mix of
silent, missense, and nonsense mutations (Fig. 3C).
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Fig. 2. Genetic intratumor heterogeneity in primary tumor and lymph node metastases. Phylogenetic trees and heatmaps based on all
mutations from each sample (silent, missense, and nonsense). (A) Phylogenetic trees. Patient 2, the seven LNMs cluster together indicating
a common origin. Patient 1, tumor areas cluster together; however, each area contains multiple private mutations. The length of the
branches corresponds to the number of mutations separating the samples; n-value indicates the total number of mutations. (B) Heatmaps
illustrating allele frequency (AF) of SNVs (green/blue scale). Regional mutations were excluded if < 10 reads in uncalled samples. A common
ancestral block of mutations was observed for both patients. Patient 2, the red box marks the mutations only called in the metastatic clone
(present in all LNMs but only in tumor area 2 of the primary tumor). The orange box marks the mutations that are only called in the
nonmetastatic cell clone (present in all tumor areas, but not in the LNMs). Patient 1, LNMs have no clear connection to a certain area of the
tumor. (C) Illustration of genetic subclones in primary tumor biopsies and metastases in patient 2. The metastatic clone is only found in one
of three biopsies and hence not the dominant clone in the primary tumor.
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Fig. 3. Genetic intratumor heterogeneity in primary tumor and spheroids. (A) Phylogenetic trees based on all called SNVs from primary
tumor biopsies and spheroid cultures. The length of the branches corresponds to the number of mutations separating the samples; n-value
indicates the total number of mutations (T = tumor; S = spheroid). (B) Heatmaps based on all SNVs. Green/blue scale indicates AF. A large
block of shared mutations are common for all patients. Nevertheless, all samples have private mutations (yellow and orange boxes) and
pairwise private mutations between tumor biopsy and matched spheroid (red boxes). For patient 2, the mutations characterizing the
nonmetastatic and the metastatic clones (given in Fig. 2) are indicated on left and right side of the heatmap. Nearly all mutations from the
nonmetastatic clone were present in all samples. Only in S3 a few mutations were undetected. These are listed. The mutations specific to
the metastatic clone were primarily observed in T2, although a few were also seen in S2 at low AFs. (C) Private and pairwise private
mutations are a mix of silent, missense, and nonsense mutations. (D) Distribution of coding SNVs (%) comparing tumor only, spheroid only,
pairwise private, and concordant mutations for each area. (E) Distribution of coding SNVs (%) comparing all tumor biopsies for each patient.
The degree of ITH varies between patients. (F) Distribution of coding SNVs (%) comparing all spheroid cultures from each patient.
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When looking only at the coding SNVs (Fig. 3D), the
concordance between the biopsy and spheroid from
each area varied from 40 to 70%. The pairwise private
SNVs represent a minor fraction (mean 5%), while the
SNVs private for either the primary tumor biopsy
(mean 24%) or spheroids (mean 17%) constitute a lar-
ger part. Looking only at the ITH of coding SNVs in
the primary tumor (Fig. 3E), it is clear that the level
of ITH varied between patients. This variation was
mimicked in the spheroid cultures (Fig. 3F), indicating
that high ITH is associated with high divergence
between spheroid cultures.
3.4. Selection for tumor driver mutations through
CNAs
In addition to point mutations, allelic imbalances and
CNAs were also called from the exomes using the tool
FACETS (Shen and Seshan, 2016). For each patient,
the analysis revealed an extensive level of structural
genomic variation between regional biopsies and
spheroids. For example for pt. 5, differences in CNAs
were observed in several areas of nearly all chromo-
somes. In general, the CNAs detected in the spheroid
cultures had higher amplitudes and were more uniform
than in the matching primary biopsy, indicating that a
larger fraction of the cells in spheroids contained the
CNA (e.g., chr.3, Fig. S1). In Fig. 4A, the CNAs of
chr.17 are plotted for each sample from pt. 5. Com-
mon for all samples are loss of the short arm of
chr.17, leading to loss of heterozygosity (LOH) at the
TP53 locus. In contrast, each biopsy and spheroid cul-
ture showed a near unique copy number pattern for
the long arm of chr.17. Some samples show LOH
along the whole long arm, while in others, only parts
of the long arm are affected. Often the retained allele
is duplicated or triplicated (fully or partially) leading
to regions with uniparental disomy and trisomy (illus-
trated in Fig. 4B). A region close to the telomere-end
of the q-arm stands out. It contains a missense muta-
tion in the RPTOR gene with an AF close to one in
many samples. The high AF combined with multiple
different amplification patterns of the region suggests
that the mutation occurred prior to the CNAs
(Fig. 4A). Of the observed q-arm mutations, only the
RPTOR mutation reached an AF close to one,
indicating that only the RPTOR mutation was present
prior to the CNAs. RPTOR, together with mTOR, is
a part of the mTORC1 complex, which is known to
play a major role in carcinogenic cell signaling (Kim
et al., 2017; Wang and Zhang, 2014). RNA sequencing
data from spheroids S2 and S3 showed that only the
mutated RPTOR allele was expressed consistent with
the other allele being lost (Fig. S2A). Taken together,
this indicates that the mutated RPTOR may create a
selective advantage and play an important role in the
tumor progression, which in this case have led to par-
allel evolution on CNA level resulting in different copy
number gains of the mutated RPTOR. To test this
hypothesis, we used cBioPortal.org (Cerami et al.,
2012; Gao et al., 2013) to analyze the overall survival
of CRC patients with and without RPTOR mutations
using a provisional TCGA cohort (n = 633) (Fig. S2B)
(Available at: http://bit.ly/2tbMjVk). These data indi-
cate that mutations in RPTOR on either SNV or
CNA level may be associated with a lower survival,
which supports the possible tumor driving function of
RPTOR.
3.5. Classification of molecular subtypes
Recently, it has been shown that CRC consists of sev-
eral molecularly and clinically distinct tumor subtypes
(Bramsen et al., 2017; Guinney et al., 2015), which are
defined by both the cancer cells and surrounding stro-
mal and immune cells (Bramsen et al., 2017). To inves-
tigate whether ITH influences classification of CRC
tumors into tumor subtypes, we performed RNA
sequencing and extracted transcriptional profiles for
the biopsies and spheroids from which sufficient mate-
rial was available (sample overview available in
Table S2). We assigned molecular subtypes to each
sample using our previously reported TUMOR sub-
type classifier (Bramsen et al., 2017), the CMS classi-
fier (Guinney et al., 2015), and the cancer cell CRIS
classifier (Isella et al., 2017). The latter reportedly only
includes epithelial transcripts and reports on the can-
cer cell subtype, while the TUMOR and CMS classi-
fiers include both epithelial and nonepithelial
transcripts (stromal and immune cell transcripts) and
reports on overall tumor subtype. Nearly all biopsies
from the same patient were classified with the same
Fig. 4. Parallel evolution: selection of different clones with multiple copies of mutated RPTOR obtained through different chromosomal
alterations leading to copy number alterations (CNAs). (A) CNAs for chr.17 are plotted for all samples from patient 5. CNA analysis of the
exomes using FACETS revealed variations in CNAs between samples. Mutational AF, relation between minor and major allele, copy
number, and cell fraction estimate (cf-em) are plotted. (B) Illustration of chr. 17 for all samples from patient 5. LOH of 17p-arm (incl. TP53)
and uniparental disomy or trisomy of 17q-arm with mutated RPTOR. Different fractions of the 17q-arm (with the mutated RPTOR) are
gained, which indicates that the mutation occurred prior to the CNAs and that multiple copies of the mutated RPTOR give an advantage.
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TUMOR (1 of 16 biopsies with deviant subtype) and
CMS subtype (2 of 16 biopsies with deviant subtype)
(Fig. 5A). By contrast, classification according to the
CRIS subtypes indicated a higher degree of transcrip-
tional ITH at the cancer cell level (7 of 16 biopsies
with deviant subtype, Fig. 5A), which supports the
genetic ITH observed by WES (Fig. 3).
Taken together, this suggests that while the tumor
cell type composition, as evaluated by the TUMOR
and CMS subtypes, is largely similar between biopsies
from the same tumor, the cancer cells within each
biopsy can be molecularly different. The biopsies from
patient 4 illustrate this point. Both the TUMOR and
CMS classifiers assigned the same subtype to all three
biopsies (T1–3), while the CRIS classifier indicated that
at the transcriptional level the cancer cells in biopsy T3
were different from those in T1 and T2 (Fig. 5A). Cor-
relation analysis based on FPKM levels of epithelial-
derived transcripts supported this finding (Fig. 5B).
Also genetically, the cancer cells of T3 differed from
those of T1 and T2 (Fig. 5C). At the genome-wide
level, the gross changes in DNA copy number levels
were mimicked in RNA expression profiles (Fig. 5C),
suggesting that the assignment of the CRIS subtypes
may be driven indirectly by genetic ITH.
It has been reported that tumor subclassification sys-
tems based on both epithelial and nonepithelial tran-
scripts could show a variation depending on sampling
site, which is primarily due to differences in the frac-
tion of nonepithelial cells in the biopsies (Dunne et al.,
2016). However, the few samples with deviant
TUMOR and CMS subtype assignments in our study
had tumor purities that were indifferent from the other
biopsies, indicating that this was not the explanation
here. Therefore, we speculate that deviant biopsies
have a different composition of nonepithelial cell types
than the other biopsies, for example, a shift in the
stromal-to-immune cell ratio.
4. Discussion
We performed WES on primary CRC biopsies and
matching spheroid cultures derived from multiple
spatially distinct sites of each tumor from five
patients. Furthermore, we included WES analysis of
LNMs for two of the patients. We found spatial
genetic ITH within all the primary tumors on both
SNV and CNA levels. Well-known early tumor dri-
vers such as APC, TP53, and KRAS were shared
among all samples in concordance with previous stud-
ies of ITH in CRC (Hardiman et al., 2016; Kim
et al., 2015). The mutation events in other driver
genes were often regional and subclonal with lower
AFs (Fig. 1F). Interestingly, we found that the muta-
tional pattern of the metastatic clone in one patient
with seven LNMs was only found in one of three
regions in the primary tumor (Fig. 2). This means
that if only a single biopsy of the primary tumor had
been analyzed, the metastatic clone could easily have
been missed. As the standard in the clinic today is
mutational analysis of a single biopsy, this could
easily have been the case. Multiple biopsies from spa-
tially distinct sites of the tumor improve the chance
of identifying ancestral targets. However, in this case,
not all the mutations shared between the primary
tumor biopsies were observed in the LNMs. Without
the information about the LNMs, these mutations
would have appeared to be ancestral. At the same
time, the mutations present in the metastatic clone
would appear as private for one of the areas, and
therefore as less important targets. This underlines
the complications that ITH brings for both biomarker
development and treatments strategies.
Patient-derived 3D tumor models may be used to
perform drug screens prior to patient treatment.
However, it is unclear how well these models recapit-
ulate the ITH of the primary tumor. Unlike most
previous studies of patient-derived models (Sch€utte
et al., 2017; van de Wetering et al., 2015), we estab-
lished multiple spheroid cultures from distinct sites of
each tumor. This approach allowed us to investigate
the spatial ITH of CRC and how well it was reflected
in the spheroids. Each spheroid culture resembled the
area of origin more than other tumor areas. This
indicates that the spatial genetic ITH in the tumor
was reflected in the spheroids. Furthermore, the AFs
Fig. 5. Intratumor heterogeneity as evaluated by RNA sequencing. (A) RNA sequencing-based classification of tumor samples into molecular
TUMOR subtypes (Bramsen et al., 2017), consensus molecular subtypes (CMS) (Guinney et al., 2015), and CRIS subtypes (Isella et al.,
2017). ‘Sample’ indicates the tumor/spheroid area, while ‘Sample Type’ indicates the origin of RNA. Tumor purity was evaluated by the
ESTIMATE software (Yoshihara et al., 2013). (B) Density scatter plot showing the correlation in RNA expression between biopsy sites T1–3
from patient 4 for cancer cell-associated transcripts (i.e., transcripts were only included if FPKM > 5 and if they were of epithelial origin as
devised by Isella et al. (2017)). (C) Line charts showing the differences in chromosomal copy numbers (as evaluated by FACETS) and gene
expression rank changes (‘DExpr Rank’) for the transcripts included in (B) between patient 4 tumor biopsies T1–T3 along the human
genome. The analysis indicates several regions where both copy numbers and gene expression changes differ between biopsy sites
(highlighted in red), but also that T1 and T2 have a higher overall ploidy (triploid) than T3 (diploid). Chromosomal locations are indicated.
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for the SNVs and the amplitudes of the CNAs were
typically larger in the spheroids, indicating a higher
cancer cell purity.
We detected private mutations in both primary
biopsies and spheroid cultures (Fig. 3). The private
mutations in the tumor biopsies indicate that not all
subclones are represented in the spheroids. On the
other hand, the private mutations in the spheroids are
most likely observed due to a selection of rare sub-
clones, which increases the detection level compared to
the primary tumor. As the primary tumor biopsies
generally have lower tumor purities than the spheroid
cultures, it cannot be excluded that increasing their
read depth would also increase the overlap in identi-
fied mutations. The spheroids were only short-term-
cultured, less than 8 days; hence, we find it unlikely
that the private mutations were acquired during cul-
ture. Another explanation could be that even though
the tumor cells used for sequencing and for spheroid
formation originated from the same biopsy, they were
nevertheless not identical due to local ITH. In a
recent study by the OncoTrack consortium, both
PDO and patient-derived xenografts (PDX) cultures
were established from a large number of patients
(Sch€utte et al., 2017). They established PDO models
from a single biopsy per tumor. For some patients,
sibling pairs of PDO and PDX models were gener-
ated. The study showed a varying resemblance
between the primary tumor and derived models, with
up to 80% discordance in the observed SNVs and
indels, which was suggested to be explained by ITH.
For most patients, 20–40% discordance between the
sibling models was observed. Whether this was due
to ITH or differences in selection pressure between
models is unknown. In the present study, we found
that each spheroid culture contained a mean of 17%
private mutations. Consequently, by establishing
spheroid cultures from multiple distinct tumor sites, a
greater knowledge of the genetic landscape of the
entire tumor is obtained. The heterogeneity of coding
SNVs between spheroids from the same patient might
cause phenotypic variation between cultures. Hence,
establishing multiple spheroids per patient increases
the representation of the different genetic subclones
present in the primary tumor. Consequently, drug
testing may become more accurate, as there will be a
greater chance of discovering a potentially resistant
clone, as exemplified by pt. 2 where the metastatic
clone was only observed in one of three spheroid cul-
tures. It is near impossible to ensure that all sub-
clones are present in the cultures; hence, there is a
potential risk of missing clinically important informa-
tion which could lead to unsuccessful patient
treatment. It should be taken into consideration that
predominantly cancer cells grow in the spheroid cul-
tures, lowering the stromal and immune components
leading to a reduced representation of the tumor as
such. Cancer cells in a primary tumor are highly
influenced by the microenvironment including the
stromal and immune cells, which might influence their
drug sensitivity (Junttila and de Sauvage, 2013). The
present spheroid model will only capture drugs that
have a direct effect on the cancer cells. Such mecha-
nisms are carried by most of the currently used thera-
peutic principles for the treatment of CRC.
Coculturing of spheroids with stromal/immune cells
may expand the chemosensitivity testing of drugs
that, for example, target the immune system (Adjei
and Blanka, 2015). Nevertheless, further studies are
needed, particularly involving larger numbers of
patients and preferably in parallel with spheroid drug
screening, to fully establish the importance of ITH
and the effect of multiple biopsies.
Transcriptional subclassification has recently been
proven to resolve most of the intertumor heterogeneity
observed in CRC, thereby enabling improved strategies
for biomarker development (Bramsen et al., 2017).
Here, we wanted to investigate how genetic ITH influ-
ences the precision of both tumor and cancer cell sub-
classification. Bearing in mind the considerable genetic
ITH, we observed that the tumor subtypes (TUMOR
and CMS) were surprisingly stable, which contrasted
the cancer cell subtypes (CRIS) that showed major
variation. We speculate that this may reflect the CRIS
subtypes and the genetic ITH both being measures of
the cancer cells, while the tumor subtypes are more
stable because they reflect both the epithelial and
nonepithelial cells in the samples.
It has been reported that also tumor subtype classi-
fiers may show a variation depending on sampling site
(Dunne et al., 2016). However, this was primarily
observed for biopsies collected at the tumor front
where obviously the fraction of nonepithelial cells is
likely to vary from biopsy to biopsy. Importantly, all
biopsies used in this study were collected from the
luminal side of the tumor and within the morphologi-
cal border of the tumor, which may explain why we
find the tumor subtype assignments robust and largely
independently of biopsy site.
Accordingly, in our hands, one biopsy may in most
cases be sufficient for TUMOR and CMS subtype
classification, although three or more biopsies would
provide a more robust subtype. CRIS classification, on
the other hand, calls for multiple biopsies per tumor.
Further studies are needed to determine the appropri-
ate number of biopsies and biopsy sites.
144 Molecular Oncology 12 (2018) 132–147 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Intratumor heterogeneity of CRC and spheroids S. S. Arnadottir et al.
5. Conclusion
In conclusion, this study provides insight into the
advantages of sampling multiple areas of the primary
CRC tumor and establishing spheroid cultures from
each area. A single biopsy from a tumor is a random
look into the components of the tumor and therefore
varies depending on the sampling site. When establish-
ing spheroids from a single tumor biopsy, only a frac-
tion of the subclones from the tumor will be present
simply due to spatial ITH. However, by sampling mul-
tiple distinct sites of the tumor, the representation of
the tumor subclones will increase and thereby auto-
matically heighten the insight into the properties of the
tumor. Transcriptional tumor subtyping seems to be
largely independent of genetic ITH and site of biopsy.
This suggests that a single biopsy may be sufficient for
tumor subclassification. By contrast, transcriptional
cancer cell subtyping (by CRIS) appears to be heavily
affected by genetic ITH and multiple biopsies will
likely be required to get the full picture of the CRIS
subtypes in a tumor.
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